First Tracks Biotherapeutics (TRAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, First Tracks Biotherapeutics (TRAX) has a cash flow conversion efficiency ratio of -0.189x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.92 Million) by net assets ($168.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see First Tracks Biotherapeutics (TRAX) total market value for the company's overall valuation and market capitalisation.
First Tracks Biotherapeutics - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how First Tracks Biotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of First Tracks Biotherapeutics for real-time trading data and today's change.
First Tracks Biotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of First Tracks Biotherapeutics ranked by their cash flow conversion efficiency. Review TRAX financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
0.046x |
|
Xiamen Wanli Stone Stock Co Ltd
SHE:002785
|
0.275x |
|
Yibin Tianyuan Group Co Ltd
SHE:002386
|
0.021x |
|
Lindsay Corporation
NYSE:LNN
|
0.013x |
|
SeAH Bestee
KO:001430
|
0.026x |
|
Hanza AB
ST:HANZA
|
0.066x |
|
Trupanion Inc
NASDAQ:TRUP
|
0.051x |
|
Wuxi Dk Electronic Materials Co Ltd
SHE:300842
|
0.282x |
Annual Cash Flow Conversion Efficiency for First Tracks Biotherapeutics (2023–2025)
The table below shows the annual cash flow conversion efficiency of First Tracks Biotherapeutics from 2023 to 2025. Also see TRAX asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $287.49 Million | $-142.93 Million | -0.497x | -54.75% |
| 2024-12-31 | $391.60 Million | $-125.81 Million | -0.321x | -41.57% |
| 2023-12-31 | $409.85 Million | $-93.00 Million | -0.227x | -- |
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in bo… Read more